888-776-0942 from 8 AM - 10 PM ET
DUBLIN , May 27, 2022 /PRNewswire/ -- The "Cancer Cachexia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global cancer cachexia market reached a value of US$ 1.88 billion in 2021. Looking forward, the market is projected to reach a value of US$ 2.53 billion by 2027, exhibiting a CAGR of 4.80% during 2022-2027. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cancer cachexia refers to a multifactorial, host-phagocytic, wasting syndrome that is characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite and muscle atrophy. It is caused due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy. Amongst these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, whereas corticosteroid assists in mitigating inflammation and suppressing overactive immune systems.
The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia.
Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, non-pharmacological therapies and clinical trials is acting as another growth-inducing factor. In line with this, the extensive utilization of several appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, for improving digestion is also contributing to the market growth.
Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms and benefits of using advanced treatments are creating a positive outlook for the market.
The competitive landscape of the industry has also been examined along with the profiles of the key players being AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma. Key Questions Answered in This Report
Key Topics Covered: 1 Preface 2 Scope and Methodology
3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Cancer Cachexia Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Therapeutics 6.1 Progestogens 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Corticosteroids 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Combination Therapy 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Others 6.4.1 Market Trends 6.4.2 Market Forecast 7 Market Breakup by Mode of Action 7.1 Appetite Stimulators 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Weight Loss Stabilizers 7.2.1 Market Trends 7.2.2 Market Forecast 8 Market Breakup by Distribution Channel 8.1 Hospital Stores 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Retail Pharmacy 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Online Pharmacy 8.3.1 Market Trends 8.3.2 Market Forecast 9 Market Breakup by Region 10 SWOT Analysis 11 Value Chain Analysis 12 Porters Five Forces Analysis 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 AAVogen Inc. 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.2 Actimed Therapeutics Ltd. 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.3 Aphios Corporation 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.4 Artelo Biosciences Inc. 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.5 AVEO Pharmaceuticals Inc. 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis 14.3.6 Fresenius Kabi AG (Fresenius SE & Co. KGaA) 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 SWOT Analysis 14.3.7 Helsinn Healthcare SA 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.8 Merck & Co. Inc. 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 NGM Biopharmaceuticals Inc. 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.10 Pfizer Inc. 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis 14.3.11 Tetra Bio-Pharma 14.3.11.1 Company Overview 14.3.11.2 Product Portfolio 14.3.11.3 Financials
For more information about this report visit https://www.researchandmarkets.com/r/v6mh9e
Research and Markets Laura Wood , Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
More news releases in similar topics
Cision Distribution 888-776-0942 from 8 AM - 9 PM ET